Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00006244 · OUTCOME

Initial Response to Therapy

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma · Source last updated 2017-07-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Evaluated at Day +84-90 Post-Transplant

What was measured

Evaluate initial response to therapy (complete remission, partial remission, stable response, or progression of disease)

Groups in this outcome

Immunotherapy Treatment

Patients receive melphalan IV over 2-3 hours on day -2 and an infusion of IL-2-treated autologous or syngeneic peripheral blood stem cells on day 0. Beginning on day 0, patients also receive IL-2 IV continuously over 5 days followed by 2 days off. Treatment with IL-2 repeats weekly for 4 weeks. Beginning 1 month later, patients undergo maintenance therapy comprising interferon alfa SC 3 times a week in the absence of disease progression or unacceptable toxicity. melphalan: Given IV recombinant interferon alfa: Given SC aldesleukin: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion in vitro-treated peripheral blood stem cell transplantation: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Immunotherapy Treatment36

Reported measurements

Patients in Complete Remission
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Immunotherapy Treatment15Not reportedNot reportedNot reportedNot reported
Patients in Partial Remission
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Immunotherapy Treatment8Not reportedNot reportedNot reportedNot reported
Patients with Stable resposne
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Immunotherapy Treatment10Not reportedNot reportedNot reportedNot reported
Patients with Disease Progression
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Immunotherapy Treatment3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        15
    title
    Patients in Complete Remission
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        8
    title
    Patients in Partial Remission
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        10
    title
    Patients with Stable resposne
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Patients with Disease Progression
denoms
  1. counts
    1. group Id
      OG000
      value
      36
    units
    Participants
description
Evaluate initial response to therapy (complete remission, partial remission, stable response, or progression of disease)
groups
  1. description
    Patients receive melphalan IV over 2-3 hours on day -2 and an infusion of IL-2-treated autologous or syngeneic peripheral blood stem cells on day 0. Beginning on day 0, patients also receive IL-2 IV continuously over 5 days followed by 2 days off. Treatment with IL-2 repeats weekly for 4 weeks. Beginning 1 month later, patients undergo maintenance therapy comprising interferon alfa SC 3 times a week in the absence of disease progression or unacceptable toxicity. melphalan: Given IV recombinant interferon alfa: Given SC aldesleukin: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion in vitro-treated peripheral blood stem cell transplantation: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
    id
    OG000
    title
    Immunotherapy Treatment
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Evaluated at Day +84-90 Post-Transplant
title
Initial Response to Therapy
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice